Why scientists are racing to develop more COVID antivirals

Norge Nyheter Nyheter

Why scientists are racing to develop more COVID antivirals
Norge Siste Nytt,Norge Overskrifter
  • 📰 Nature
  • ⏱ Reading Time:
  • 60 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 68%

The world will soon need more COVID antivirals – here’s why

Credit: YONHAP/EPA-EFE/Shutterstock

“These are our first-generation antivirals against coronaviruses,” says Sara Cherry, an immunologist at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Our experience with antivirals against other diseases, like hepatitis C and HIV, proves that “we can do better and better over time”, she adds.

It’s too soon to tell whether SARS-CoV-2 is likely to develop any resistance to these first-generation antivirals, says Tim Sheahan, a coronavirologist at the University of North Carolina at Chapel Hill. Although its sky-high rate of replication is a breeding ground for mutations, he says, the virus also causes acute infections that offer relatively little time for resistance-causing mutations to accumulate.

Other antiviral drug candidates are slowly working their way through the clinical-trial pipeline, says Carl Dieffenbach, director of the division of AIDS at the US National Institute of Allergy and Infectious Diseases . He says that one promising candidate is a protease inhibitor, developed by Shionogi & Company, based in Osaka, Japan, and Hokkaido University in Japan, that is currently in phase II/III clinical trials in Asia.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

Nature /  🏆 64. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Why scientists are racing to develop more COVID antiviralsThe first crop of antivirals against SARS-CoV-2 is promising. But new drugs will be needed to counter the looming threat of resistance.
Les mer »

Terrifying Post-COVID Syndrome Makes Comeback in South Carolina KidsTerrifying Post-COVID Syndrome Makes Comeback in South Carolina KidsBranson Diven didn’t even know he’d been infected—until his organs were ravaged and he was on the brink of death.
Les mer »

FDA acts to expand use of treatment for COVID-19 patients with mild-to-moderate diseaseFDA acts to expand use of treatment for COVID-19 patients with mild-to-moderate diseasePreviously, the use of Veklury, a Gilead Sciences Inc. drug, was limited to those requiring hospitalization.
Les mer »

For L.A. 'battlefield hospital,' latest COVID surge comes with a familiar rhythmFor L.A. 'battlefield hospital,' latest COVID surge comes with a familiar rhythmOfficials say the Omicron variant has flooded the emergency room at Martin Luther King, Jr. Community Hospital, ground zero for hospitals besieged by a winter surge, with people who are not as sick.
Les mer »



Render Time: 2025-04-12 16:23:51